British-Swedish pharmaceutical giant AstraZeneca has announced a landmark $50 billion investment in the United States by 2030, significantly expanding its research, development, and manufacturing footprint in its largest global market.
The move comes as the Trump administration considers tariffs of up to 200% on pharmaceutical products manufactured outside the United States—a policy shift aimed at encouraging domestic production and reducing reliance on foreign drug supply chains.
Strategic Expansion to Meet Revenue and Drug Pipeline Goals
The new investment builds on a $3.5 billion pledge made in November 2024, and is part of AstraZeneca’s broader ambition to reach $80 billion in global revenues by 2030, with 50% of that expected from the U.S. market. According to the company, the investment will support its plan to launch 20 new medicines by the end of the decade.
“The U.S. plays a critical role in our global operations,” said Pascal Soriot, AstraZeneca’s Chief Executive Officer. “This announcement reflects our confidence in American innovation in biopharmaceuticals and our dedication to improving patient outcomes.”
New Manufacturing Hub in Virginia
At the heart of the investment is a multi-billion-dollar manufacturing facility to be constructed in Virginia. The site—AstraZeneca’s largest single-facility investment to date—will focus on the production of treatments for chronic diseases, particularly within the weight management and metabolic therapy sectors.
Governor Glenn Youngkin welcomed the announcement, highlighting the Commonwealth’s commitment to advancing high-skilled jobs in science and technology. The facility is expected to enhance the domestic pharmaceutical supply chain and reduce dependence on international production.
Broader U.S. Expansion
In addition to the Virginia project, AstraZeneca’s investment will fuel expansions in Massachusetts, Maryland, California, Indiana, and Texas, while supporting new clinical trial sites across the country.
Currently, AstraZeneca operates 19 R&D, manufacturing, and commercial sites in the U.S., which represents 42% of its global revenue. The company employs over 18,000 people and supports an estimated 92,000 jobs nationwide. The new investment is projected to generate tens of thousands of additional jobs over the next five years.
U.S. Officials Applaud Domestic Shift
U.S. Secretary of Commerce Howard Lutnick praised the move, stating that American dependence on foreign-made drugs has long been a national vulnerability.
“President Trump’s tariff policies are designed to correct this structural weakness,” Lutnick said. “AstraZeneca’s decision to invest $50 billion and produce medicines in America is historic. It not only strengthens our domestic pharmaceutical supply chain but also creates tens of thousands of jobs for Americans.”
As tariff threats and supply chain concerns intensify, AstraZeneca’s strategic shift positions it as a key player in reshaping the future of pharmaceutical manufacturing in the United States.
